BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• DNA damaging agents are crucial in sarcoma chemotherapy but have significant toxicities.
• There is a critical need for novel chemotherapeutic agents with improved efficacy and safety profiles for sarcoma treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of BO-1055, a novel DNA damaging agent, against various sarcoma types.
• To investigate the mechanism of action and therapeutic potential of BO-1055 in preclinical sarcoma models.

Main Methods:

• In vitro assays including cell proliferation, apoptosis, and DNA damage markers (γ-H2AX, comet assay) in sarcoma and benign cell lines.
• In vivo studies using patient-derived xenograft (PDX) and xenograft models of sarcoma.
• Drug combination studies with irinotecan in Ewing sarcoma PDX models.

Main Results:

• BO-1055 demonstrated potent, dose- and time-dependent apoptosis and cell death in sarcoma cell lines, particularly Ewing sarcoma and rhabdomyosarcoma.
• The agent induced significant DNA double-strand breaks and γH2AX expression in cancer cells compared to benign cells, indicating a selective toxicity.
• BO-1055 inhibited tumor growth and induced regression in multiple sarcoma xenograft models, including cyclophosphamide-resistant Ewing sarcoma, and synergized with irinotecan.

Conclusions:

• BO-1055 exhibits potent anti-sarcoma activity and a favorable therapeutic window compared to existing DNA damaging drugs.
• Its ability to induce DNA damage selectively in cancer cells and demonstrate efficacy in resistant models supports its further development as a sarcoma therapeutic agent.